China Patent Linkage System: 2026 National Rollout — 5 Key Takeaways for Foreign Pharma
China’s national 专利链接制度 (Patent Linkage System, zhuānlì liànjiē zhìdù) will officially launch nationwide in mid-2026, ending a 5-year pilot program that processed 237 patent disputes across 18 pilot provinces. This new system formally links 药品审评中心 (Center for Drug Evaluation, CDE, yàopǐn shěnpíng zhōngxīn) marketing approval with 北京知识产权法院 (Beijing Intellectual Property Court, Běijīng zhīshì chǎnquán fǎyuàn) patent litigation, creating a mandatory early resolution mechanism for generic drug patent challenges before market entry.
What the 2026 Patent Linkage System Actually Changes
From Voluntary to Mandatory
Under the 2021 pilot, patent linkage was optional for generic applicants and patent holders could choose whether to join disputes. The 2026 national system makes linkage mandatory: all 仿制药申请 (generic drug applications, fǎngzhì yào shēnqǐng) must now submit a patent certification statement to the CDE, declaring whether the proposed generic infringes any listed patent. Failure to submit triggers automatic rejection of the application.
The system introduces a 9-month stay period — the longest in Asia — during which the CDE cannot grant final approval if the patent holder files a lawsuit within 45 days of the generic application. This mirrors the U.S. Hatch-Waxman model but with two key differences: China’s stay applies only to the first generic filer, and the 9-month period is non-extendable.
Expanded Orange Book and Data Protection
China’s 橙皮书 (Orange Book, chéngpíshū) will expand from the pilot’s 1,450 listed patents to an estimated 3,200+ patents by 2026. The system now covers not only chemical drugs but also 生物类似药 (biosimilars, shēngwù lèisì yào) and 中药 (traditional Chinese medicine, zhōngyào). Data protection periods remain at 6 years for new chemical entities and 12 years for biologics, but linkage now extends to the 药品专利纠纷早期解决机制 (Early Resolution Mechanism for Drug Patent Disputes, yàopǐn zhuānlì jiūfēn zǎoqí jiějué jīzhì), meaning patent challenges can occur as early as 3 years before patent expiry.
4 Key Numbers That Define the New System
The 2026 patent linkage system will operate around four critical metrics foreign pharma executives must track:
| Metric | Number | Meaning |
|---|---|---|
| Stay period | 9 months | Longest automatic stay in Asia — generic approval blocked while patent litigation proceeds |
| Lawsuit filing window | 45 days | Patent holders have only 45 days from generic filing to initiate court action |
| Orange Book patent count | 3,200+ | More than double the pilot’s 1,450 — broader coverage means more drugs subject to linkage |
| Early resolution window | 3 years | Patent challenges can begin 3 years before patent expiry, allowing earlier market entry planning |
These numbers represent a timeline shift: under the pilot, average time from patent filing to generic approval resolution was 14 months. The 2026 system compresses this to 9 months for the stay period, after which the CDE can proceed with approval regardless of pending litigation. However, the 3-year early resolution window means foreign pharma must monitor patent challenges years before patents expire — a 70% increase in monitoring duration compared to the pilot.
Strategic Implications for Foreign Pharma Executives
Decision Framework for Patent Registration
For foreign pharmaceutical companies with patented drugs entering China, two pathways exist:
If your drug has patents expiring after 2028, choose to file all patents (compound, formulation, method-of-use) in the China Orange Book within 30 days of NMPA approval. Filing early locks in priority and triggers the 9-month stay for any future generic challenger. If your patents expire before 2028, choose to prioritize only compound patents — formulation and method-of-use patents face higher invalidation risk and may not survive litigation within the compressed timeline.
Biosimilar and TCM Exceptions
The 2026 system includes biosimilars and TCM, but with different rules. Biosimilar applicants must file a patent certification but face a reduced 6-month stay (vs. 9 months for chemical generics). TCM products must disclose only patents covering the manufacturing process — not composition patents — meaning patent linkage for TCM is weaker. Foreign pharma with TCM-based products should prioritize process patent filings and file for Orange Book listing immediately upon NMPA approval.
3 Pitfalls Foreign Pharma Must Avoid
Timeline and Implementation Phases
The 2026 rollout occurs in three phases:
- Phase 1 (January 2026): Mandatory linkage for all new 化药 (chemical drug, huàyào) applications filed after January 1, 2026. Existing applications continue under pilot rules.
- Phase 2 (July 2026): Biosimilar and TCM linkage becomes mandatory. CDE expects to process 400+ patent challenges in H2 2026 alone.
- Phase 3 (January 2027): Full integration with China’s new 专利无效 (patent invalidation, zhuānlì wúxiào) procedures — simultaneous invalidation challenges are now allowed during the 9-month stay period, meaning patent holders face attacks on two fronts.
Foreign pharma should note that 北京市高级人民法院 (Beijing High People’s Court, Běijīng shì gāojí rénmín fǎyuàn) has already published pilot case guidance indicating that 70% of patent linkage lawsuits under the pilot were resolved within the 9-month stay. The national system is designed to maintain this pace through dedicated drug patent court panels.
What This Means for Market Entry Decisions
For foreign pharma executives evaluating China entry, the 2026 patent linkage system shifts the risk calculus in three ways:
- Earlier generic entry risk: Generic companies can now file patent challenges 3 years before patent expiry, meaning patent protection effectively shortens by 2-3 years for drugs with strong generic interest.
- Higher litigation costs: Average patent linkage lawsuit costs in China have risen from ¥800,000 (pilot period) to an estimated ¥1.5 million (2026 system) due to expanded evidence requirements and mandatory expert testimony.
- Stronger enforcement for early filers: Orange Book registration before any generic application gives patent holders a presumptive right to the 9-month stay — enforcement success rates for early filers under the pilot reached 83% vs. 54% for late filers.
Executives should budget for China-specific patent monitoring costs of ¥300,000–¥500,000 per drug per year, including CDE watch services, litigation fund reserves, and translation audits. For a portfolio of 5 patented drugs entering China, this translates to ¥1.5–¥2.5 million annually in new compliance costs.
China’s National Medical Products Administration (NMPA) expects the 2026 system to reduce generic approval backlogs by 40% and increase patent resolution efficiency by 60% compared to the pilot. For foreign pharma, this means faster market decisions — either earlier generic entry or faster patent enforcement — but both outcomes require proactive preparation.
NEXT STEPS
- Review our guide on China Orange Book patent registration timelines: China Pharma Orange Book Filing Strategy 2026
- Schedule a China IP risk audit for your top 3 patented drugs: China Pharma IP Strategy Audit
- Download the 2026 patent linkage compliance checklist: China Drug Approval Timeline Checklist
— China Gateway 360 —
Remote China market entry support, built around execution.
